NEW YORK (GenomeWeb News) – Biofield today said that it has licensed exclusive worldwide distribution rights, outside of Belgium, to ValiRx's human papillomavirus diagnostic test as well as its HyperGenomics and Nucleosomics cancer diagnostic products.
The products are being developed by ValiBio, a Belgian joint venture between the UK's ValiRx and the Institut de Pathologie et de Genetique, which houses ValiBio's operations.
The HPV test is being developed to detect infection by any of the known 15 high-risk HPV subtypes, according to ValiRx's website. The HyperGenomics platform includes differential diagnostic tests being developed for a variety of cancers, and the Nucleosomics platform includes non-invasive tests for detecting early cancer through epigenetic signal changes.
Philadelphia-based Biofield is developing its own diagnostic system for the early detection of breast cancer. The firm said that it aims to generate revenue from sales of this system to customers in foreign markets while acquiring other non-invasive detection and prevention technologies.